The survival rate in 12 months after Bioda ‘artificial blood vein’ operation is over 95%

‘The survival rate in 12 months after Bioda ‘artificial blood vein’ operation is over 95%.’ the reporter learnt from Jiangsu Bioda Life Science Co., Ltd. that the enterprise published the multi-center clinical trial data of ‘artificial blood vein’ over the state in Shanghai for the first time. Clinical trial shows that the safety and effectiveness of Bioda ‘artificial blood vein’ is proved completely.

Jiangsu Bioda is located at Nantong north high and new tech development district. It was founded by American born Chinese Doctor Du Guangwu in 2016. It works on research and development and manufacture of high end medical equipment and consumables such as artificial blood vein and intravascular stent. In November 2022, VASOLINE® artificial blood vein researched and developed by Jiangsu Bioda got the registration certificate of class three medical equipment from National Medical Products Administration, and its batch production is realized in the beginning of the year. It is also the first ‘artificial blood vein’ which was approved and batch production was realized, and has independent intellectual property rights in China.

By Miao Bei and Lu Chenghui